# Soochow University Nanohybrids Mitigate Glucocorticoid Bone Loss in Rats

- Published: 2026-11-06 14:20 UTC
- Section: Life & Health › Medicine
- Tags: peptide oligonucleotide nanohybrid, glucocorticoid-induced bone loss, miR-26a-5p delivery, targeted bone therapy, osteogenesis angiogenesis coupling
- URL: https://realtech.media/news/rt-cdb74b365277e343e4e2140e_soochow_university_nanohybrids/

**Engineers developed a peptide-oligonucleotide platform to deliver miR-26a-5p directly to injured skeletal sites in animal models.**

![Soochow University Nanohybrids Mitigate Glucocorticoid Bone Loss in Rats](https://sgzwpqqelzmajkcubgkl.supabase.co/storage/v1/object/public/rt-media/2026/11/bc9bce9ac3ba5e0e.jpg)
*U.S. Navy photo by Matthew Reyes, Wikimedia Commons, Public domain*

Researchers from Soochow University, Zhejiang University, and Nanyang Technological University have developed a pathology-adapted peptide-oligonucleotide nanohybrid (PON) designed to counteract glucocorticoid-induced bone loss (GIBL) [1]. Glucocorticoid exposure often triggers systematic osteopenia and osteonecrosis of the femoral head, presenting a clinical challenge due to the simultaneous deterioration of bone architecture and local microvasculature [1]. As reported in Nature Communications, the targeted modular delivery platform was engineered to deliver microRNA-26a-5p directly into injured osseous environments [1].

## Targeted Nanohybrid Architecture

The PON design incorporates several functional features, including molecular self-assembly, affinity for bone tissue, enzyme-triggered responsiveness, cell-penetrating capabilities, and endosomal-lysosomal escape mechanisms [1]. Together, these characteristics overcome traditional systemic transport barriers associated with oligonucleotide therapeutics, shielding the cargo and improving localization within glucocorticoid-damaged microenvironments [1]. Systemic distribution of native oligonucleotides typically suffers from rapid degradation and low target-tissue bioaccumulation, issues addressed by this integrated delivery system [1].

## Molecular Pathways and In Vivo Efficacy

Mechanistically, the targeted delivery of miR-26a-5p suppressed glycogen synthase kinase-3 beta (GSK-3β) expression and promoted the stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) [1]. This dual effect sustained osteogenesis-angiogenesis coupling while reducing cellular apoptosis under glucocorticoid exposure [1]. In rat disease models, systemic administration of the nanohybrids protected against initial skeletal and vascular degradation and limited pathological progression in established conditions [1].

## Sources

1. [Nature Communications](https://doi.org/10.1038/s41467-026-79320-z)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-cdb74b365277e343e4e2140e_soochow_university_nanohybrids/